Literature DB >> 9705176

Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay.

E Beirnaert1, B Willems, M Peeters, A Bouckaert, L Heyndrickx, P Zhong, K Vereecken, S Coppens, D Davis, P Ndumbe, W Janssens, G van der Groen.   

Abstract

An enzyme-linked immuno-sorbent assay (ELISA) for the detection of human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIVcpz/SIVmnd) antigens was designed using immunoreagents from naturally infected individuals, and compared to the commercially available Vironostika HIV-1 Antigen Microelisa System (Organon Teknika). The in-house assay proved to be specific for HIV-1 isolates belonging to group M (A-H) and group O and for SIVcpz and SIVmnd isolates, but was less sensitive than the Vironostika HIV-1 Antigen Microelisa System, except for SIVmnd. For the strains belonging to HIV-2, SIVmac and SIVagm, the in-house assay could not detect antigen to an appreciable degree. This study shows that a considerably less expensive but sufficiently accurate HIV-1 antigen capture assay can be developed to monitor HIV-1 (group M and O), SIVcpv and SIVmnd antigen in the supernatants of virus cultures.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705176     DOI: 10.1016/s0166-0934(98)00044-5

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  14 in total

1.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficiency virus type 1 infection in chimpanzees.

Authors:  Jonathan L Heeney; Erik Rutjens; Ernst J Verschoor; Henk Niphuis; Peter ten Haaft; Scott Rouse; Hazel McClure; Sunita Balla-Jhagjhoorsingh; Willy Bogers; Mary Salas; Kathy Cobb; Luc Kestens; David Davis; Guido van der Groen; Valerie Courgnaud; Martine Peeters; Krishna K Murthy
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Transcriptome analysis of monocyte-HIV interactions.

Authors:  Rafael Van den Bergh; Eric Florence; Erika Vlieghe; Tom Boonefaes; Johan Grooten; Erica Houthuys; Huyen Thi Thanh Tran; Youssef Gali; Patrick De Baetselier; Guido Vanham; Geert Raes
Journal:  Retrovirology       Date:  2010-06-14       Impact factor: 4.602

5.  Characterization of a monoclonal anti-capsid antibody that cross-reacts with three major primate lentivirus lineages.

Authors:  Brigitte E Sanders-Beer; Magdalena Eschricht; Janna Seifried; Vanessa M Hirsch; Jonathan S Allan; Stephen Norley
Journal:  Virology       Date:  2011-12-05       Impact factor: 3.616

6.  A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

Authors:  Yven Van Herrewege; Guido Vanham; Jo Michiels; Katrien Fransen; Luc Kestens; Koen Andries; Paul Janssen; Paul Lewi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.

Authors:  Katty Terrazas-Aranda; Yven Van Herrewege; Daria Hazuda; Paul Lewi; Roberta Costi; Roberto Di Santo; Andrea Cara; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

8.  MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.

Authors:  Katrijn Grupping; Philippe Selhorst; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Pascal Kessler; Guido Vanham; Loïc Martin; Kevin K Ariën
Journal:  Retrovirology       Date:  2012-05-02       Impact factor: 4.602

9.  Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT.

Authors:  Rafael Van den Bergh; Sébastien Morin; Hans Jürgen Sass; Stephan Grzesiek; Marc Vekemans; Eric Florence; Huyen Thanh Thi Tran; Rosina Gabriel Imiru; Leo Heyndrickx; Guido Vanham; Patrick De Baetselier; Geert Raes
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

10.  Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness.

Authors:  Antoinette C van der Kuyl; Karolina Kozaczynska; Kevin K Ariën; Youssef Gali; Victoria R Balázs; Stefan J Dekker; Fokla Zorgdrager; Guido Vanham; Ben Berkhout; Marion Cornelissen
Journal:  Retrovirology       Date:  2010-07-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.